Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $53 to $57.
June 18, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Michael Ulz maintains an Overweight rating on Mirum Pharmaceuticals and raises the price target from $53 to $57.
The Overweight rating and increased price target from a reputable analyst at Morgan Stanley are likely to boost investor confidence and positively impact the stock price of Mirum Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100